about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersDetectable clonal mosaicism and its relationship to aging and cancerImputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesThe interaction of PP1 with BRCA1 and analysis of their expression in breast tumorsMADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinomaCell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancersFamilial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene.Genome-wide association studies identify four ER negative-specific breast cancer risk lociCommon breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersMultigene testing of moderate-risk genes: be mindful of the missenseThe Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancerGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskEWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesisIdentification of rare variants in the hLIMD1 gene in breast cancerLarge-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repairEpigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesisAltered expression and deletion of RMO1 in osteosarcomaPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSRare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancersRare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening studyGenome-wide association study identifies two susceptibility loci for osteosarcomaRare mutations in XRCC2 increase the risk of breast cancerRare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening studyLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age.Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European DescentIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.A role for the TGFbeta-Par6 polarity pathway in breast cancer progressionMale breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)Application of reliability coefficients in cDNA microarray data analysis.SNP-SNP interactions in breast cancer susceptibility.Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis.Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk.TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer
P50
Q21144874-D37A082A-576D-4D28-95AD-4F870182B9C4Q23916196-DC00A2EA-CAB5-48FF-B307-757ADAAEC6F6Q23924183-15FB058E-C477-4876-A151-3AE3933189E8Q24170413-FF823516-2E21-44F0-AB6A-3531CF74C9D6Q24306302-0F588E19-B8DD-436C-AA50-69F2D7C67CACQ24315119-21A64A1D-47E3-4762-8991-2493B0B9027AQ24329205-06F8C6B2-DBFA-47CD-969F-8E3B34F2FAC2Q24539146-78DED53A-2D88-4AD9-A52E-663CCEB409FAQ24622610-AC743E1B-A9A8-47BB-A903-D7D490A22C1BQ24655824-3EF45FD9-523E-467F-A790-E10C13BBE54CQ24658557-6BAC2685-31AD-4C8E-98A5-1E90E8431A5EQ24806109-D107BAA4-664B-466E-992D-EF05ADD433E0Q27008356-F494F048-C720-4221-952D-249CE52A3B8EQ27851507-D5254F8E-D43A-47C2-884E-2F43E4817308Q27851709-EB5006F9-51F4-4753-A955-E20573639345Q28240820-832FA15F-9B14-482B-B4EE-B981479E3F74Q28250209-D5B3F8A5-29E4-4F20-8AB3-38154BD2849FQ28267893-1587BEF6-5403-4B02-9E9E-FFF88DE29B09Q28288212-F719D45D-D7A4-4787-BF6B-87D0158D1EA0Q28299137-22EEDCDA-D877-4298-AF05-746055BD16D2Q28584533-0B064CFD-29EA-4A87-9A59-50EDADD10353Q28652056-1A547B1C-979A-4041-BAD3-81ACB6610261Q28652308-75903888-C3EF-451E-93BD-2303C4BC2DEDQ28659642-89D0CE5D-31F1-4BED-9BDD-8BFA618B9B6CQ28730692-20152E19-D492-4BC0-848D-59CCF16B6DDDQ28743906-1658A094-1001-49A7-87C2-0FAB24FF28CBQ29416989-80AB9198-67D0-43C0-8B9F-A55784D26EA9Q29417036-4E8FCC1A-6BEB-46E4-8330-F1A36CE9250EQ29417068-273EE74B-D873-42A8-9950-CF81F99D74D0Q30000080-9544FC57-79F7-4C4B-A45B-DEE893BC342DQ30252854-0B698C2A-7B93-4767-80C4-8AD1B2D19455Q30374367-2EE75F32-68CD-4E77-BC57-DA3FABB375C0Q30489618-786A25D4-BB1D-4718-BC98-4AA762AC5448Q31043651-1454E7D8-4DD2-4BA2-8BA6-841459231C07Q31082788-98772B0C-8DCB-4426-8970-03432280BDE3Q33229208-23999886-03AF-482B-BA81-F92F1BF791E8Q33242109-8770D9F4-0FC1-4897-A8C5-FB83640ADC16Q33287624-FEB94C77-BD77-4388-BFE2-E43FFB3566FBQ33314644-754405A2-69E0-4BB0-806C-E1E4285BFCE8Q33566957-E51E2BBE-0E8D-4DA3-ABBB-796CB5CC18CC
P50
description
Canadees onderzoekster
@nl
forsker
@nb
hulumtuese
@sq
kanadische Forscherin
@de
researcher
@en
taighdeoir
@ga
name
Irene L Andrulis
@ast
Irene L Andrulis
@en
Irene L Andrulis
@es
Irene L Andrulis
@ga
Irene L Andrulis
@nl
Irene L Andrulis
@sl
Irene L Andrulis
@sq
Irene L. Andrulis
@da
Irene L. Andrulis
@de
Irene L. Andrulis
@fr
type
label
Irene L Andrulis
@ast
Irene L Andrulis
@en
Irene L Andrulis
@es
Irene L Andrulis
@ga
Irene L Andrulis
@nl
Irene L Andrulis
@sl
Irene L Andrulis
@sq
Irene L. Andrulis
@da
Irene L. Andrulis
@de
Irene L. Andrulis
@fr
altLabel
Irene Andrulis
@nb
Irene L Andrulis
@en
prefLabel
Irene L Andrulis
@ast
Irene L Andrulis
@en
Irene L Andrulis
@es
Irene L Andrulis
@ga
Irene L Andrulis
@nl
Irene L Andrulis
@sl
Irene L Andrulis
@sq
Irene L. Andrulis
@da
Irene L. Andrulis
@de
Irene L. Andrulis
@fr
P106
P21
P27
P31
P496
0000-0002-4226-6435